Medtronic (MDT) valuation
Medtronic P/E ratio history
Medtronic trades at 23.8 times its earnings over the last twelve months and 15.9 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 22.3 (year to Apr 2026) to 49.2 (year to Apr 2021), with a median of 28.4.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Apr 24, 2026 | $83.32 | $3.73 | 22.3 | 14.0 |
| Apr 25, 2025 | $84.16 | $3.61 | 23.3 | 14.7 |
| Apr 26, 2024 | $79.74 | $2.76 | 28.9 | — |
| Apr 28, 2023 | $90.95 | $2.82 | 32.3 | 17.3 |
| Apr 29, 2022 | $104.36 | $3.73 | 28.0 | 18.0 |
| Apr 30, 2021 | $130.92 | $2.66 | 49.2 | — |
| Apr 24, 2020 | $99.30 | $3.55 | 28.0 | — |
| Apr 26, 2019 | $87.35 | $3.42 | 25.5 | — |
| Apr 27, 2018 | $81.29 | $2.26 | 36.0 | — |
| Apr 28, 2017 | $83.09 | $2.89 | 28.8 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Medtronic valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| MedtronicMDT | $124B | 23.8 | 15.9 | 3.3 |
| StrykerSYK | $112B | 30.2 | 18.6 | 4.3 |
| Intuitive SurgicalISRG | $153B | 52.4 | 35.6 | 13.2 |
| Abbott LaboratoriesABT | $185B | 34.3 | 18.5 | 4.0 |
| Boston ScientificBSX | $62.4B | 17.0 | 13.2 | 3.0 |
| Becton DickinsonBDX | $54.5B | 74.5 | 15.1 | 2.6 |
| Edwards LifesciencesEW | $53.0B | 52.9 | 28.9 | 8.1 |
| Idexx LaboratoriesIDXX | $43.5B | 38.7 | 34.9 | 9.6 |
| GE HealthCareGEHC | $34.6B | 16.2 | 14.3 | 1.6 |
| Peer median | 36.5 | 18.6 | 4.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: MDT financials · MDT returns
No forecast, no recommendation. This page describes Medtronic from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.